Biomea Fusion (BMEA) closed at $0.58 on November 13, 2026, up 3.4% from the previous close, on volume of 550,825 shares (30-day average 2,103,476).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Call Spread | 21-Jan-282 : 2.5 C | 500 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Biomea Fusion to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Piper Sandler Sticks to Their Buy Rating for Biomea Fusion (BMEA)
TipRanks (Wed, 11-Nov 8:36 AM ET)
Biomea’s Advancing Diabetes Pipeline and Obesity Potential Support Buy; $4 Price Target Maintained
TipRanks (Wed, 11-Nov 6:55 AM ET)
TipRanks (Wed, 11-Nov 5:35 AM ET)
Biomea Fusion GAAP EPS of -$0.09 beats by $0.11
Seeking Alpha News (Tue, 10-Nov 4:57 PM ET)
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Tue, 13-Oct 4:08 PM ET)
Globe Newswire (Mon, 12-Oct 4:30 PM ET)
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Globe Newswire (Wed, 23-Sep 7:03 AM ET)
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Biomea Fusion trades on the NASDAQ stock market under the symbol BMEA.
As of November 13, 2026, BMEA stock price climbed to $0.58 with 550,825 million shares trading.
BMEA has a beta of 2.95, meaning it tends to be more sensitive to market movements. BMEA has a correlation of 0.11 to the broad based SPY ETF.
BMEA has a market cap of $42.31 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BMEA traded as high as $22.74 and as low as $.54.
The top ETF exchange traded funds that BMEA belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
BMEA has underperformed the market in the last year with a price return of -57.5% while the SPY ETF gained +11.5%. BMEA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.5% and -6.5%, respectively, while the SPY returned -2.1% and -1.9%, respectively.
BMEA support price is $.52 and resistance is $.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMEA shares will trade within this expected range on the day.